The news of a dispute between the EU and AstraZeneca over the delayed supply of Covid-19 vaccinations has been the cause of much debate over the past week.
This prompted The Times to ask Waterfront Partner Alison Berryman for her thoughts on the wording on the contract, the potential for litigation to arise out of the dispute and in particular if AstraZeneca could cite the force majeure clause as a reason for the delays.
Alison commented that the pandemic “has certainly thrown force majeure clauses into the spotlight”, she also said that “despite citing production delays as their rather vague explanation for the delayed delivery of vaccines to the EU, Astrazeneca doesn’t appear to be trying to rely on its force majeure clause at the present time”.
Alison’s comments featured in The Times and can be read here.
The National Security and Investment Act 2021 came into force came into force on 4 January 2022 and introduced the first stand-alone regime for screening acquisitions and investments to protect UK national security.
On 19th November 2025, the European Commission announced proposed changes to the AI Act, following their commitment to a “clear, simple, and innovation-friendly implementation of the AI Act.”
What Are The EBA Outsourcing Guidlines? The European Banking Authority (EBA) Outsourcing Guidelines aims to…